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Tolerance to Islet Antigens and
Prevention from Diabetes Induced by
Limited Apoptosis of Pancreatic  Cells
immune responses rarely occur. At least two mecha-
nisms could account for this phenomenon. In some
cases, self-Ag are ignored because they are seques-
tered in immunologically privileged sites (Miller and
Heath, 1993). Alternatively, self-peptides are readily pre-
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was demonstrated for CD4 T cells in mice expressing
either the SV40 large T Ag or influenza hemagglutinin in
the pancreatic  cells (Adler et al., 1998; Fo¨rster et al.,
1995; Fo¨rster and Lieberam, 1996). In both cases, Ag-Summary
specific CD4 T cells were activated in the pancreatic
LN before being either deleted or anergized.Crosspresentation of self-antigens by antigen-pre-
Apoptotic cell death facilitates the entry of self-Agsenting cells is critical for the induction of peripheral
into the crosspresentation pathway (Albert et al., 1998a,tolerance. As apoptosis facilitates the entry of anti-
1998b; Kurts et al., 1998, 1999; Steinman et al., 2000).gens into the crosspresentation pathway, we sought
In vitro studies have shown that immature dendritic cellsto prevent the development of autoimmune diabetes
(DCs) can efficiently present Ag derived from apoptoticby inducing pancreatic cell apoptosis before disease
cells to MHC class I- and MHC class II-restricted T cellsonset. Accordingly, young nonobese diabetic (NOD)
(Albert et al., 1998b; Austyn, 1999; Gallucci et al., 1999;mice injected with a single low dose of streptozotocin
Inaba et al., 1998; Sauter et al., 2000). Likewise, in vivo(SZ), a drug cytotoxic for  cells, exhibited impaired
studies using transgenic mice expressing OVA in pan-T cell responses to islet antigens and were protected
creatic  cells have shown that peripheral Ag expressedfrom spontaneous diabetes. Furthermore,  cell apo-
at low levels did not enter the crosspresentation path-ptosis was necessary for protection since SZ did not
way unless released by CTL-mediated tissue destruc-protect RIP-CrmA transgenic NOD mice in which 
tion (Kurts et al., 1998, 1999). Although the mechanismscells expressed the caspase inhibitor CrmA. Our re-
involved in the capture and the processing of self-Agsults support a model in which apoptosis of pancreatic
have been poorly characterized, it was shown that im- cells induces the development of regulatory cells
mature DCs could ingest apoptotic cells and that thisleading to the tolerization of self-reactive T cells and
uptake was mediated by CD36 and v5 (Albert et al.,protection from diabetes.
1998a; Rubartelli et al., 1997; Urban et al., 2001). Further-
more, apoptotic cells, as well as antibodies against
CD36 or CD51, inhibit the maturation of human DCs andIntroduction
their ability to respond to inflammatory signals (Urban
et al., 2001). If Ag derived from apoptotic cells are pre-Tolerance to self-antigens (Ag) is one of the key features
sented by immature DCs, what are the effects of thisthat characterizes the immune system. Although most
phenomenon on the immune system? Repetitive stimu-autoreactive T cells are deleted in the thymus, some
lation of PBL with allogeneic immature human DCs hasescape thymic deletion and migrate to the periphery.
been shown to induce the development of IL-10-produc-These peripheral autoreactive T cells are believed to
ing CD4 T cells, which were able to inhibit Th1 immuneexpress a naive phenotype and could potentially cause
responses (Jonuleit et al., 2000). Furthermore, injectionautoimmunity upon engagement of their TCR. Despite
of Ag-pulsed immature DCs into influenza-vaccinatedthe emergence of these potentially harmful T cells, auto-
individuals induced the development of IL-10-producing
CD8 T cells and downregulation of influenza-specific
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tory cells and the establishment of T cell tolerance Results
(Steinman et al., 2000; Mellman and Steinman, 2001;
The Administration of a Single Low Dose of SZRoncarolo et al., 2001).
Protects NOD Mice from Spontaneous DiabetesAlthough most autoreactive T cells are either eliminated
To determine whether a single injection of SZ inducedor tolerized, some individuals nevertheless develop auto-
the apoptosis of pancreatic  cells, we injected femaleimmune diseases. In the case of insulin-dependent dia-
NOD mice with various doses of this drug. We preparedbetes mellitus (IDDM), autoreactive T lymphocytes infil-
pancreatic islets 3 hr later and measured the frequencytrate the pancreatic islets and cause the death of the
of apoptotic cells by propidium iodide staining of frag-insulin-producing  cells, eventually resulting in diabe-
mented nuclei. Apoptotic cells were readily detected intes. This phenomenon has been extensively studied in
SZ-treated mice (Figure 1A). Indeed, the frequency ofnonobese diabetic mice (NOD) mice, which spontane-
cells exhibiting fragmented nuclei increased in a dose-ously develop IDDM (Delovitch and Singh, 1997). In the
dependent manner from 6.3% in mice treated with bufferinitial phase, which begins between 3 and 4 weeks of
alone to 29.8% and 56.8% in those treated with 40 andage and which is observed in all mice, T cells and other
200 mg/kg, respectively. To confirm that SZ induced leucocytes infiltrate the perivascular duct and peri-islet
cell apoptosis, islets from SZ-treated mice were pre-regions of the pancreatic islets of Langerhans. This
pared and incubated for 12 hr in vitro in low-glucosestage, called peri-insulitis, is followed in 80%–90% of
medium. This was done to allow for the detection ofthe females and 20%–40% of the males by a more inva-
 cells on the basis of high autofluorescence due to
sive and destructive insulitis, which leads to the destruc-
intracellular flavin adenine dinucleotide (FAD) as de-
tion of the pancreatic  cells. Considerable evidence
scribed (Van de Winkel et al., 1982). The frequency of
suggests that IDDM in NOD mice is mediated by autore- Annexin V-positive, 7-AAD-negative  cells increased in
active T cells. IDDM is prevented by neonatal thy- a dose-dependent manner from 7% in mice injected
mectomy, by immunosuppressive agents that target with buffer alone to 92% in those injected with 200
T cells, and by anti-CD4 and anti-CD8 mAb treatments. mg/kg of SZ (Figure 1B). Since low doses of SZ induced
Furthermore, splenocytes or T cell clones isolated from  cell apoptosis, we sought to determine whether this
spontaneously diabetic NOD mice adoptively transfer drug could protect NOD mice from spontaneous diabe-
diabetes when they are injected into neonatal NOD mice tes. To this aim, we injected 4-week-old female NOD
or into NOD mice that are homozygous for the SCID mice with either buffer alone, 40, or 60 mg/kg of SZ.
mutation (Bendelac et al., 1987; Haskins and McDuffie, Mice were monitored for insulitis at the ages of 5, 6,
1990). While the fate of diabetogenic T cells has not and 9 weeks, and for diabetes until they were 25 weeks
been followed because of the lack of suitable reagents, old. At all times after injection, both the number of infil-
their development was shown to be dependent on the trated islets and the severity of insulitis were higher in
presence of target  cells (Larger et al., 1995). SZ-treated mice as compared to those injected with
Transgenic mice expressing Ag in peripheral tissues buffer alone (Figure 2A). However, SZ did not grossly
have been instrumental in demonstrating the existence modify the composition of the islet infiltrate as demon-
of crosstolerance. However, it is not clear whether such strated by flow cytometry analysis following staining
with anti-CD4, anti-CD8, anti-CD19, anti-CD11b, andmechanisms are at work in more physiological situa-
anti-CD11c mAb (data not shown). Although insulitistions. Moreover, it remains to be demonstrated whether
was more severe in SZ-treated mice, these animals de-immunological or pharmacological manipulations aimed
veloped diabetes less frequently than control animalsat favoring crosspresentation of self-Ag could be used
(Figure 2B). Thus, while 65% of buffer-treated animalsto prevent autoimmune responses. In this study, we
became diabetic within 25 weeks, only 22% and 28% ofsought to determine whether the induction of limited
the mice injected with 60 and 40 mg/kg of SZ developedpancreatic  cell death before the onset of IDDM in NOD
diabetes during the same period (p  0.006 and p mice could prevent the development of spontaneous
0.01, respectively). We next investigated whether SZdiabetes. To achieve this goal, we have treated NOD
could confer protection in another model of autoimmunemice with streptozotocin (SZ), a drug which is rapidly
diabetes. To this aim, C57BL/6-derived RIP-LCMV-NPmetabolized by  cells and eventually induces their
mice that selectively expressed the NP LCMV proteindeath (Kolb, 1993; Leiter, 1982). Experiments were also
in pancreatic  cells were infected with LCMV and in-
performed on transgenic NOD mice in which the bovine
jected 4 weeks later with 60 mg/kg of SZ or buffer alone.
poxvirus serpin-like CrmA protein was selectively ex- As previously reported (von Herrath et al., 1994), most
pressed in pancreatic  cells. This viral protein, which of the mice that had not been treated with SZ (12/13)
is a potent inhibitor of several caspases, was shown developed diabetes within 12 weeks postinfection. In
to protect mammalian cells from apoptosis induced by contrast, none of the SZ-treated animals (0/8) became
diverse manipulations, including growth factor with- diabetic during the 9 months of the observation period
drawal and triggering of CD95 or TNF- (Tewari and (Figure 2C).
Dixit, 1995). Here, we show that a single injection of SZ To confirm that the protective effect of SZ was medi-
protects NOD mice from spontaneous diabetes. As SZ ated through  cell apoptosis, we generated transgenic
does not prevent diabetes in mice in which  cells are NOD mice in which the inhibitor of apoptosis CrmA was
protected from apoptosis by the transgenic expression selectively expressed in  cells. Three transgenic lines,
of CrmA, our data suggest that limited  cell apoptosis RIP-CrmA-27, -51, and -79, were obtained and further
may be beneficial to the host by inducing the tolerization analyzed. To determine whether RIP-CrmA transgenic
mice were protected from diabetes, these mice and theirof potentially harmful T cells.
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Figure 1. SZ Induces  Cell Apoptosis
Six-week-old NOD mice were injected with the indicated doses of SZ. Islets were harvested 3 hr later, incubated for 12 hr in low glucose
medium, and dispersed into single cells.
(A) Cells were incubated in a PI-containing hypotonic solution, and nuclei were analyzed 15 hr later. Data show typical flow cytometry profiles
and the percentages of cells exhibiting fragmented nuclei.
(B) Cells were stained with PE-conjugated Annexin V and 7-AAD and analyzed. Data show typical flow cytometry profiles after gating on
autofluorescent FAD cells. The percentage of Annexin V-positive 7-AAD-negative cells is indicated.
negative littermates were either monitored for spontane- from diabetes induced by diabetogenic splenocytes
(Figures 3A and 3B). Thus, only 1/6 and 1/7 RIP-CrmA-27ous diabetes for 30 weeks or irradiated and further in-
jected with splenocytes from diabetic NOD mice. While and RIP-CrmA-51 mice, respectively, became diabetic
between 12 and 25 days after transfer as compared toRIP-CrmA-51 and RIP-CrmA-27 transgenic mice devel-
oped spontaneous diabetes with the same incidence nontransgenic recipients, all of which became diabetic
during the same period. The third strain of transgenicand kinetics as their negative littermates (Figure 4C and
data not shown), they were almost completely protected mice, RIP-CrmA-79, exhibited only partial protection
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Figure 2. SZ Results in Accelerated Insulitis
and Protects from Diabetes
(A) Four-week-old female NOD mice were in-
jected with either 40 mg/kg of SZ (right panel)
or buffer alone (left panel). Mice were killed
at the ages of 5, 6, and 9 weeks, and their
pancreata were scored for evidence of no
insulitis (empty bars), peri- or light (gray bars),
moderate (hatched bars), or severe (filled
bars) insulitis. Each histogram bar corre-
sponds to one individual mouse.
(B) Four-week-old female NOD mice (20 mice
per group) were injected with either buffer
alone (empty circles), or 40 mg/kg (filled
squares) or 60 mg/kg (filled circles) of SZ.
Mice were monitored for glycosuria.
(C) Six-week-old RIP-LCMV-NP mice were in-
fected on day 0 with 1  105 pfu of LCMV.
Four weeks later, mice were injected (filled
circles) or not (empty circles) with a single
dose (60 mg/kg) of SZ. Animals were moni-
tored by measuring blood glucose levels.
from adoptively transferred diabetes and was not ana- from RIP-CrmA-51 and RIP-CrmA-27 transgenic mice
were incubated with sCD95L, the frequency of apoptoticlyzed further (Figure 3C).
To test whether the CrmA transgene protected  cells cells increased from 12% to 19% and 17%, respectively.
As CrmA is an inhibitor of apoptosis, we expectedfrom apoptosis, islets from RIP-CrmA-51 and RIP-
CrmA-27 transgenic mice and from their negative lit- that  cells from RIP-CrmA transgenic mice would be
protected from SZ-induced apoptosis. To confirm this,termates were incubated in vitro with IL-1 and IFN-
with or without soluble CD95L (sCD95L). Two days later, RIP-CrmA-51 transgenic mice and their negative lit-
termates were injected either with 60 mg/kg of SZ orislets were dispersed into single cells and the frequency
of apoptotic  cells was measured by propidium iodide with buffer alone. Mice were killed 3 hr later and islets
were prepared and incubated in vitro for 12 hr in low-staining. In agreement with previous studies (Thomas
et al., 1999), IL-1 and IFN- induced pancreatic  cells glucose medium. Apoptosis was measured by propid-
ium iodide staining of fragmented nuclei. In contrast toto express CD95 within 24 hr (data not shown). When
islets from NOD mice were incubated with sCD95L, the nontransgenic NOD mice in which the injection of SZ
resulted in an increased frequency of cells with frag-proportion of  cells undergoing apoptosis increased
from 13% to 32% (Figure 3D). In contrast, when islets mented nuclei (6% versus 26%), this treatment had no
Crosstolerance in NOD Mice
173
Figure 3.  Cells from RIP-CrmA Transgenic Mice Are Protected from Apoptosis
(A–C) Eight-week-old male (A) RIP-CrmA-27, (B) RIP-CrmA-51, or (C) RIP-CrmA-79 transgenic mice (filled circles) and their sex-matched
negative littermates (open circles) were irradiated and injected with 1.3  107 splenocytes from diabetic NOD mice. Mice were monitored for
glycosuria.
(D) 150–200 islets from RIP-CrmA-51 and RIP-CrmA-27 transgenic mice and from their negative littermates (NOD) were incubated for 60 hr
with IL-1 and IFN- with (filled bars) or without (empty bars) sCD95L (150 ng/ml). Islets were dispersed into single cells, incubated in a
hypotonic fluorochrome solution, and nuclei were analyzed 15 hr later by flow cytometry. Data show mean and SD from two experiments.
effect in RIP-CrmA-51 transgenic mice (Figure 4A). In were impaired in their ability to adoptively transfer dia-
betes when injected into immunodeficient recipients. Toother experiments, islet cells were dispersed and
stained with Annexin V and 7-AAD. As expected, NOD investigate this possibility, 4-week-old female NOD mice
were treated with either SZ or buffer alone. Splenocytesmice treated with SZ exhibited a higher frequency of
Annexin V-positive, 7-AAD-negative  cells than NOD were prepared 4 weeks later and injected into NOD SCID
mice. While 70% of the mice injected with splenocytesmice injected with buffer alone (28% versus 16%) (Figure
4B). In contrast, the frequency of Annexin V-positive from buffer-treated mice became diabetic during the
26-week observation period, only 6% of the animals7-AAD-negative cells was similar in SZ- and buffer-
treated RIP-CrmA-51 transgenic mice. Thus, the trans- injected with splenocytes from SZ-treated mice became
diabetic during the same period (p  0.0003) (Figuregenic expression of CrmA protected islet  cells from
SZ-induced apoptosis. 5A). In agreement with our results showing that SZ did
not protect RIP-CrmA transgenic mice from spontane-Since  cells from RIP-CrmA transgenic mice were
protected from SZ-induced apoptosis, we next inves- ous diabetes (Figure 4), splenocytes from 8-week-old
SZ-treated RIP-CrmA-51 mice were only slightly lesstigated whether the protective effect of SZ would be
abrogated by the expression of CrmA. To this aim, diabetogenic than those from buffer-treated animals
(p  0.45) (Figure 5B).4-week-old female RIP-CrmA-51 transgenic mice and
their sex-matched negative littermates were injected As both CD4 and CD8 T cells are required for the
development of diabetes (Bendelac et al., 1987), wewith either SZ or buffer alone. While nontransgenic mice
developed diabetes less frequently when treated with investigated which of these two T cell subsets was im-
paired as the result of SZ treatment. To address thisSZ than when treated with buffer alone (27% versus
66%, p  0.018), RIP-CrmA-51 transgenic mice exhib- issue, splenocytes from buffer- and SZ-treated mice
were depleted of either CD4 or CD8 T cells. Conse-ited the same incidence of diabetes upon injection of
SZ or upon injection of buffer alone (p  1.0) (Figure 4C). quently, mixtures (1:1) of the aforementioned CD4- or
CD8-depleted splenocytes were adoptively transferred
into RAG-2-deficient NOD mice. As previously observedIslet-Specific CD4 T Cell Responses
when total splenocytes from buffer- and SZ-treatedAre Impaired in SZ-Treated Mice
mice were transferred into NOD SCID mice (Figure 5A),Since SZ-treated NOD mice were protected from diabe-
tes, we sought to determine whether their splenocytes RAG-2-deficient mice injected with a mixture of CD4-
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Figure 4. SZ Does Not Protect RIP-CrmA
Transgenic Mice from Spontaneous Diabetes
(A and B) Six-week-old female RIP-CrmA-51
transgenic mice and their negative littermates
(NOD) were injected with either SZ (60 mg/
kg) or buffer alone, and islets were harvested
3 hr later. (A) The frequency of cells exhibiting
fragmented nuclei was determined as de-
scribed in Figure 1(A). Data show mean and
SD from two experiments. (B) The proportion
of apoptotic  cells was determined by stain-
ing with Annexin V and 7-AAD as described
in Figure 1(B). Data show mean and SD from
two experiments.
(C) Four-week-old female RIP-CrmA-51
transgenic mice (triangles) and their negative
littermates (circles) were injected with either
SZ (60 mg/kg) (filled symbols) or buffer alone
(open symbols). Mice were monitored weekly
for glycosuria. The number of mice in each
group is indicated.
depleted cells and CD8-depleted cells from buffer- (Figure 5C and data not shown). When splenocytes from
both groups of mice were depleted of CD4 T cells, thetreated mice developed diabetes more frequently than
those injected with cells from SZ-treated mice (15/15 secretion of IFN- was totally abrogated. In contrast,
depletion of CD8 T cells led to only a slight decreaseversus 6/15 animals) (Table 1). Furthermore, only 53%
(8/15) of the mice injected with CD4-depleted cells from of IFN- secretion (data not shown).
The decreased islet-specific helper T cell responsesbuffer-treated mice and CD8-depleted cells from SZ-
treated mice developed diabetes. In contrast, mice in- observed in SZ-treated mice could result from either
the clonal deletion or the anergy of islet-specific CD4jected with CD4-depleted cells from SZ-treated mice
and CD8-depleted cells from buffer-treated mice devel- T cells. SZ could also promote the development of regu-
latory T cells that may prevent diabetes. To test thisoped diabetes almost as frequently as control recipients
injected with cells from buffer-treated mice (14/15 ver- latter hypothesis, splenocytes were prepared from mice
which had been treated 4 weeks earlier with SZ or buffersus 15/15). Thus, these results show that CD4 T cells
from SZ-treated mice were impaired in their ability to alone. Different numbers of these cells were mixed with
8  106 splenocytes from recently diabetic mice andadoptively transfer diabetes.
To confirm that SZ downregulated islet-specific CD4 injected into irradiated recipients. At two different cell
ratios, splenocytes from SZ-treated mice inhibited dia-T cell responses, splenocytes from 8-week-old SZ- and
buffer-treated NOD mice were incubated with or without betes more efficiently than those from buffer-treated
animals. Thus, during the 14 weeks of the observationislet cells, GAD65, anti-CD3 mAb, or ConA. Two days
later, supernatants were harvested and IFN- contents period, 50% (5/10) and 10% (1/10) of the mice injected
with 3.2  107 splenocytes from buffer- and SZ-treatedwere measured. While splenocytes from both groups of
mice secreted similar amounts of IFN- in response to mice, respectively, developed diabetes (Figure 5D). In
the same experiment, 90% (9/10) and 40% (4/10) of theeither ConA or anti-CD3 mAb, cells from SZ-treated mice
secreted 2.5- to 3-fold less IFN- when incubated with mice injected with 1.6  107 splenocytes from buffer-
and SZ-treated mice, respectively, became diabetic.islet cells or GAD65 than those from buffer-treated mice
Crosstolerance in NOD Mice
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Figure 5. Islet-Specific Immune Responses Are Impaired in SZ-Treated Mice
(A and C) Four-week-old female NOD and (B) RIP-CrmA-51 transgenic mice were treated with either SZ (60 mg/kg) (filled circles) or buffer
alone (open circles), and splenocytes were prepared 4 weeks later. (A and B) 2  107 splenocytes were injected into 6-week-old female NOD
SCID recipients (20 mice per group). Mice were monitored weekly for glycosuria. (C) 2  106 splenocytes were incubated in flat-bottom 96-
well plates with either 2  104 islet cells (left panel), GAD65 (30 g/ml) (middle panel), or ConA (2 g/ml) (right panel). Cellular supernatants
were harvested 48 hr later and IFN- contents were measured by ELISA.
(D) 8  106 splenocytes from recently diabetic mice were injected into irradiated 6-week-old male NOD mice either alone (triangles) or together
with either 1.6  107 (circles) or 3.2  107 (squares) splenocytes from mice treated with SZ (filled symbols) or buffer alone (empty symbols).
Mice were monitored weekly for glycosuria.
Thus, SZ-induced  cell apoptosis resulted in the devel- To confirm this hypothesis and to further identify the
APCs involved in this process, NOD mice were injectedopment of regulatory T cells that could inhibit the devel-
opment of diabetes induced by diabetogenic T cells. with either SZ or buffer alone. Pancreatic LN were har-
vested 2 days later, and CD11c and CD11c cells were
purified and incubated with islet-specific BW2.5-31 Cell Apoptosis Facilitates the Entry of Islet Ag into
the Crosspresentation Pathway and Induces T cell hybridoma. Supernatants were harvested 24 hr
later and analyzed for IL-2 content. CD11c cells fromthe Development of Regulatory T Cells
SZ-induced  cell apoptosis was likely to result in the SZ-treated mice induced BW2.5-31 hybridoma to se-
crete 3-fold more IL-2 than CD11c from buffer-treatedincreased presentation of islet Ag by professional APCs.
Table 1. Islet-Specific CD4 T Cell Responses Are Impaired in SZ-Treated Mice
Transferred Splenocytes Weeks Posttransfer
CD4-Depleted CD8-Depleted 6 Weeks 11 Weeks 14 Weeks
buffer buffer 0/15 (0%) 11/15 (73%) 15/15 (100%)
streptozotocin buffer 0/15 (0%) 6/15 (40%) 14/15 (93%)
buffer streptozotocin 0/15 (0%) 6/15 (40%) 8/15 (53%)
streptozotocin streptozotocin 0/15 (0%) 6/15 (40%) 6/15 (40%)
Four-week-old female NOD mice were treated with either SZ (60 mg/kg) or buffer alone. Splenocytes were prepared 4 weeks later and depleted
of either CD8 or CD4 T cells, and the indicated mixtures of 107 CD4-depleted and 107 CD8-depleted cells were injected into 8-week-old
female NOD RAG-2 KO recipients. At the indicated times after transfer, the number and the frequency of diabetic mice per group is indicated.
Immunity
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Figure 6. SZ Facilitates the Entry of Islet Ag into the Crosspresentation Pathway and Induces the Development of Regulatory Cells
(A–C) Four-week-old female NOD mice were treated with either SZ (60 mg/kg) or buffer alone, and pancreatic LN were harvested 48 hr later.
(A) LN cells were depleted of CD3 T cells, and CD11c and CD11c cells were purified using magnetic beads (left panel). CD11c cells were
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mice (Figure 6A). Furthermore, BW2.5-31 hybridoma did increase in the surface expression of these molecules
was observed in SZ-treated mice either at day 2 (Figurenot secrete any detectable amount of IL-2 when incu-
bated with CD11c cells. To identify which DCs pre- 6C) or at days 1 or 3 (data not shown). Thus, although
SZ promoted the presentation of islet Ag by CD11bsented islet Ag, CD11c cells from SZ- and buffer-
treated mice were separated into CD11b and CD11b DCs, it did not promote their differentiation into cells
exhibiting a more mature phenotype.cells, and different numbers of these cells were incu-
bated with BW2.5-31 hybridoma. In contrast to CD11b We next sought to compare the behavior of islet-spe-
cific CD4 T cells in SZ- and buffer-treated mice. ToDCs, CD11b DCs from both SZ- and buffer- treated
mice induced BW2.5-31 hybridoma to secrete IL-2. Fur- this aim, CD62Lhigh CD4 T cells from Thy1.2 BDC2.5
transgenic mice were purified and injected into 4-week-thermore, BW2.5-31 hybridoma secreted more IL-2
when incubated with CD11b DCs from SZ-treated mice old Thy1.1NOD congenic recipients. Mice were treated
the day after with either SZ or buffer alone, and pancre-than when incubated with those from buffer-treated
mice (Figure 6A). Thus,  cell apoptosis induced by SZ atic LN were harvested 5 days later (Figure 6D). CD4
T cells were purified and analyzed by flow cytometryresulted in the increased presentation of islet Ag by
CD11b DCs. following staining with anti-CD4, anti-Thy1.2, anti-CD44,
and anti-CD62L mAb. The frequency of Thy1.2 amongTo determine whether CD11b DCs from SZ-treated
mice could induce the proliferation of islet-specific CD4 cells was higher in the LN of SZ-treated mice than
in those of buffer-treated animals (3.0% versus 1.6%).CD4 T cells in vitro, CD62Lhigh CD4T cells from BDC2.5
TCR transgenic mice were labeled with CFSE and incu- Furthermore, the proportion of Thy1.2 cells exhibiting
a typical CD62LlowCD44high Ag-experienced phenotypebated with or without CD11b DCs from SZ- and buffer-
treated mice. Cells were harvested 96 hr later and T cell were 40% and 27% in SZ- and buffer-treated mice, re-
spectively.proliferation was assessed by flow cytometry by mea-
suring the decrease in CFSE fluorescence due to cell To further characterize the phenotype of Thy1.2
BDC2.5 T cells in SZ- and buffer-treated mice, thesedivision. While only 1.8% of BDC2.5 transgenic T cells
had progressed through the cell cycle when incubated cells were purified and incubated in vitro with mitomycin
C-treated syngeneic splenocytes and peptide 1040-51,alone, 30.2% and 14.1% of these T cells had divided in
response to CD11b DCs from SZ- and buffer-treated which is known to stimulate BDC2.5 T cells (Judkowski
et al., 2001). Supernatants were collected 96 hr later andmice, respectively (Figure 6B). Thus,  cell apoptosis
resulted in the presentation of islet Ag by CD11b DCs IFN-, IL-10, and IL-5 contents were measured. While
Thy1.2 cells from SZ- and buffer-treated mice secretedin vivo, and these cells were able to induce the prolifera-
tion of islet-specific T cells in vitro. identical amounts of IL-10 and undetectable amounts
of IL-5 in response to peptide 1040-51, cells from SZ-To characterize the phenotype of CD11b DCs, NOD
mice were injected with either SZ or buffer alone, and treated animals produced 2.5-fold less IFN- than those
from buffer-treated animals (Figure 6E). Thus, althoughCD11c cells were purified from the pancreatic LN 1, 2,
or 3 days later. As a positive control, CD11c cells were the frequency of CD62LlowCD44high Thy1.2 cells was
higher in SZ-treated mice, these cells secreted lessprepared from the draining LN of mice, which had been
injected 2 days earlier with LPS. Purified CD11c cells IFN- than those from buffer-treated animals.
Recent studies have shown that some T cell subsetswere stained with anti-CD11c, anti-CD11b, and either
anti-CD40, anti-CD80, anti-CD86, or anti-MHC class II can inhibit the proliferation of CD4 T cells in vitro (Saka-
guchi, 2000). To determine if cells from SZ-treated micemAb and analyzed by flow cytometry after gating on
CD11cCD11b cells. As expected, CD11b DCs from exhibited regulatory properties, different numbers of
Thy1.2 cells from either SZ- or buffer-treated mice werebuffer-treated mice expressed high levels of MHC class
II and relatively low levels of CD40, CD80, and CD86 incubated with CFSE-labeled CD62Lhigh BDC2.5 T cells
with or without peptide 1040-51. Cells were harvestedmolecules (Hawiger et al., 2001). However, in contrast
to CD11bDCs from LPS-injected mice, which exhibited 96 hr later, and T cell proliferation was assessed by flow
cytometry. In the absence of any Thy1.2 T cells, thean increased expression of CD80, CD86, and CD40, no
further separated into CD11b and CD11b DCs (right panel). The indicated numbers of cells from SZ- (filled bars) and buffer-treated (empty
bars) mice were incubated with 105 BW2.5.31 hybridoma. Supernatants were harvested 24 hr later, and IL-2 contents were measured by
ELISA. Data show the results of a representative (out of three) experiment. (B) CD62Lhigh CD4 T cells from BDC2.5 transgenic mice were
labeled with CFSE, and 3  105 cells were incubated either alone (right panel) or with 105 CD11b DCs from SZ- or buffer-treated mice (left
panel). Cells were harvested 96 hr later and analyzed after staining with anti-CD4 mAb. Typical flow cytometry profiles are shown after gating
on CD4 T cells. (C) CD11c DCs from the pancreatic LN of SZ- (thin lines) and buffer- (dotted lines) treated mice and from the popliteal LN
of LPS-injected mice (thick lines) were stained with anti-CD11c, anti-CD11b, and either anti-CD80, anti-CD86, anti-CD40, or anti-I-Ad mAb.
Typical flow cytometry profiles are shown after gating on CD11c CD11b cells.
(D–F) Thy1.2 CD62Lhigh CD4 T cells were purified from BDC2.5 TCR transgenic mice, and 5  106 cells were injected into 4-week-old Thy1.1
congenic NOD recipients. Mice were treated the day after with either SZ or buffer alone. Pancreatic LN were harvested 5 days later and CD4
T cells were purified. (D) Cells were analyzed by flow cytometry following staining with anti-CD4, anti-Thy1.2, anti-CD44, and anti-CD62L mAb.
Typical flow cytometry profiles are shown after gating on either CD4 T cells (left panels) or CD4 Thy1.2 T cells (right panels). (E) CD4
Thy1.2 T cells from SZ- (filled bars) and buffer- (empty bars) treated mice were purified, and 6  104 cells were incubated with mitomycin
C-treated syngeneic splenocytes and 5 ng/ml of peptide 1040-51. Supernatants were analyzed 96 hr later for IFN- (left panel) and IL-10 (right
panel) content. Data from a typical experiment are shown. (F) The indicated numbers of purified CD4 Thy1.2 T cells were incubated in vitro
with 2  105 CFSE-labeled BDC2.5 TCR transgenic CD62Lhigh CD4 T cells, and mitomycin C-treated syngeneic splenocytes with or without
peptide 1040-51. Cells were harvested 96 hr later and analyzed by flow cytometry after gating on CFSE-labeled CD4 T cells.
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frequency of BDC2.5 T cells that had divided increased from diabetes by SZ, RIP-CrmA transgenic mice were
not. Thus, the protection from diabetes induced by SZfrom 2% without peptide to 67% with peptide (Figure
was abrogated by the  cell-specific expression of the6F). In the presence of 6  104 Thy1.2 cells from SZ-
antiapoptotic CrmA protein, further demonstrating thatand buffer-treated mice, the frequencies of BDC2.5
SZ-induced protection was mediated through the induc-T cells that had divided in response to peptide were
tion of  cell apoptosis.22% and 37%, respectively. Furthermore, 3  104
Several lines of evidence suggested that islet-specificThy1.2 cells from SZ-treated mice were as efficient as
T cell responses were impaired as the result of SZ-6  104 Thy1.2 cells from buffer-treated animals in
induced  cell apoptosis. First, splenocytes from SZ-inhibiting the proliferation of BDC2.5 T cells (data not
treated mice were less diabetogenic than those fromshown). Thus, the increased presentation of islet Ag
buffer-treated animals as demonstrated by their im-induced by SZ resulted in the development of CD4
paired ability to transfer diabetes to NOD SCID recipi-T cells, which exhibited regulatory properties in vitro
ents. This phenomenon was not due to gross alterationsand which were impaired in their ability to secrete IFN-
in either the proportion or the absolute numbers of CD4in response to Ag stimulation.
and CD8 T cells. Further experiments suggested that
CD4 T cells, but not CD8 T cells, from SZ-treatedDiscussion
mice were impaired in their ability to adoptively transfer
diabetes to RAG-2-deficient NOD mice. In agreementThe goal of this study was to investigate whether autoim-
with this latter result, CD4 T cells from SZ-treated micemune T cell responses could be prevented by inducing
secreted less IFN- in response to both islets andlimited apoptosis in the target tissue before the onset
GAD65 than those from control animals. The impairedof the disease. To this aim, we treated young NOD mice
islet-specific T cell responses exhibited by SZ-treatedwith SZ, a drug which is rapidly metabolized by pancre-
mice did not reflect a general immunosuppression in-atic  cells and eventually induces their death (Kolb,
duced by this drug. Indeed, T cells from SZ- and buffer-1993; Leiter, 1982; O’Brien et al., 1996). Islets from mice
treated mice secreted similar amounts of IFN- wheninjected with single low doses of SZ contained both
incubated with either ConA or immobilized anti-CD3an increased frequency of Annexin V-positive, 7-AAD-
mAb.negative  cells and a higher frequency of pancreatic
How could the induction of  cell apoptosis resultislet cells with fragmented nuclei than islets from buffer-
in protection from diabetes? SZ was likely to act bytreated animals. Thus, injection of SZ induced  cell
facilitating the entry of islet Ag into the crosspresenta-apoptosis in a dose-dependent manner. In agreement
tion pathway. To test this, we have measured the abilitywith our working hypothesis, low doses of SZ, which
of CD11cand CD11ccells from SZ- and buffer-treatedwere sufficient to induce  cell death, protected 4-week-
mice to stimulate islet-specific T cell hybridoma.old NOD mice from spontaneous diabetes. The protec-
CD11c cells from SZ-treated mice were more efficienttive effect of SZ was not restricted to NOD mice. Indeed,
in stimulating islet-specific hybridoma than those froma single dose of SZ also protected C57BL/6-derived
buffer-treated animals. In contrast, neither CD11c cells
RIP-LCMV-NP mice from diabetes induced by the infec-
from SZ-treated mice nor those from buffer-treated ani-
tion with LCMV.
mals were capable of stimulating these hybridoma. As
Although SZ induces  cell apoptosis through its di-
CD11c cells have been classified into two different
rect interaction with these cells, high doses of this drug subsets depending on the expression of CD11b, we
were shown to upregulate the expression of class II have investigated which subset was presenting islet Ag.
MHC molecules on several cell types (Klinkhammer et We found no evidence that CD11b DCs from either
al., 1989) and to stimulate Th1 responses upon s.c. injec- SZ- or buffer- treated mice could stimulate islet-specific
tion (Albers et al., 1998). Thus, it was formerly possible T cells. In contrast, CD11b DCs did stimulate islet-
that the protective effect of SZ was not mediated by the specific hybridoma and TCR transgenic T cells, with
induction of  cell apoptosis. To confirm that it was not cells from SZ-treated mice being more efficient than
the case, we generated NOD-derived transgenic mice those from buffer-treated animals. Thus, although we
in which the gene coding for the antiapoptotic CrmA cannot rule out that either CD11c or CD11bCD11c
protein is driven by the  cell-specific rat insulin pro- cells may present islet Ag, our results suggest that Ag
moter. Two different strains of RIP-CrmA transgenic derived from live and/or apoptotic  cells are mainly
mice (27 and 51) were almost completely protected presented by CD11b DCs.
from diabetes induced by the transfer of diabetogenic The presentation of islet Ag induced by SZ could either
splenocytes while a third strain (79) exhibited only induce the clonal deletion of islet-specific T cells or
partial protection. Further experiments showed that  promote their differentiation into anergic or regulatory
cells from RIP-CrmA-27 and RIP-CrmA-51 transgenic cells. To address this issue, BDC2.5 T cells were injected
mice were more resistant to CD95-induced apoptosis into NOD mice, which were treated the day after with
than those from their negative littermates. The fact that either SZ or buffer alone. In SZ-treated mice, BDC2.5
we had obtained similar results in two independent T cells were present at a higher frequency, and the
transgenic lines suggested that the CrmA transgene was proportion of these cells exhibiting a CD62LlowCD44high
expressed and that its ability to protect pancreatic  phenotype was higher than in buffer-treated animals.
cells from apoptosis was really due to its product. Fur- Furthermore, while T cells from SZ-treated mice se-
ther experiments showed that pancreatic  cells from creted less IFN- than those from buffer-treated ani-
these RIP-CrmA strains were also protected from SZ- mals, they exhibited an increased ability to inhibit the
proliferation of naive BDC2.5 T cells in vitro. Interest-induced apoptosis. While NOD mice were protected
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ingly, although SZ promoted the presentation of islet may lead to the emergence of higher numbers of autore-
Ag by CD11b DCs, neither these cells nor other DCs active T cells. In agreement with this hypothesis, spleno-
exhibited signs of increased maturation upon injection cytes from 8-week-old RIP-CrmA transgenic lines ap-
of SZ. Taken together, our data are consistent with the peared to be slightly more diabetogenic than those from
notion that immature DC can capture Ag derived from their negative littermates when injected into NOD SCID
apoptotic cells under physiologic conditions and induce recipients.
peripheral T cell tolerance by promoting the develop- The results presented here suggest that the induction
ment of regulatory T cells (Mellman and Steinman, 2001). of apoptosis in peripheral tissues may prevent the devel-
Thus, in vitro studies have shown that Ag derived from opment of pathogenic self-reactive T cells. This finding
apoptotic cells could be captured and presented by could possibly lead to the development of new cellular
human (Albert et al., 1998a, 1998b; Sauter et al., 2000) therapeutic interventions in which established lines of
and murine (Gallucci et al., 1999; Inaba et al., 1998) differentiated cells would be induced to die and subse-
immature DCs without promoting their maturation. Other quently injected into susceptible individuals before the
studies performed in rats have allowed the identification onset of the disease.
of a discrete subpopulation of DCs that transported
Experimental Proceduresapoptotic intestinal epithelial cells to the T cell areas of
the mesenteric LN (Huang et al., 2000). Furthermore,
Mice and Monitoring of Diabeteshuman immature DCs were shown to induce the devel-
NOD Thy1.1 (Christianson et al., 1993), NOD SCID (Prochazka et al.,
opment of IL-10-secreting regulatory CD4 T cells in 1992), RAG-2-deficient NOD (Soderstrom et al., 1996), RIP-LCMV-
vitro (Jonuleit et al., 2000) and of IL-10-producing CD8 NP (von Herrath et al., 1994), and BDC2.5 (Katz et al., 1993) mice
T cells in vivo (Dhodapkar et al., 2001). Last, it was have been described. To generate RIP-CrmA transgenic mice, the
poxvirus CrmA cDNA was cloned downstream of the rat insulindemonstrated that Ag delivered in situ to DCs in the
promoter II into the RIP7 vector (Hanahan, 1985). Prokaryotic se-absence of maturation signals induced T cell unrespon-
quences were eliminated and the DNA was microinjected into fertil-siveness (Hawiger et al., 2001). Thus, our results, to-
ized NOD oocytes. Transgenic founder mice were identified bygether with those reported by others, suggest that 
Southern blot. Further generations of transgenic mice were
cell apoptosis may result in the release of islet Ag and screened by PCR of tail DNA. RIP-LCMV-NP transgenic mice were
in their capture by DCs. Because this phenomenon oc- infected i.p. with 105 pfu of LCMV as described (von Herrath et al.,
curred in the absence of DC maturation, the subsequent 1994). Mice were tested for glycosuria using glukotest strips (Roche
Diagnostics, Meylan, France) and were considered diabetic whenpresentation of these islet Ag induced the development
two consecutive readings were superior to 200 mg/dl.of CD4 T cells exhibiting regulatory function in vitro and
possibly in vivo. In agreement with this latter hypothesis,
Reagentssplenocytes from SZ-treated mice were more potent
SZ (Sigma, St. Quentin Fallavier, France) was dissolved in sodium
than those from buffer-treated animals in preventing citrate buffer (pH 4.0) and injected i.p. within 5 min. GAD65 was
the development of diabetes induced by diabetogenic produced as described (Laloux et al., 2001). All mAb were purchased
T cells. from Becton Dickinson SA (Le Pont de Claix, France). The peptide
1040-51 (RVLPLWVRME) (Judkowski et al., 2001) was purchasedAlthough we have generated RIP-CrmA mice to inves-
from Chiron Mimotopes (France).tigate how low doses of SZ could protect NOD mice
from diabetes, the fact that these mice were protected
Histologyfrom adoptively transferred diabetes, but not from spon-
Pancreata were fixed in alcoholic Bouin’s solution, embedded in
taneous diabetes, is potentially interesting. Different paraffin, sectioned (4 m), and stained with haematoxylin and eosin.
hypotheses may account for these latter results. First, At least 40 islets per mouse were scored for insulitis. Islets were
it is possible that  cells would die by apoptosis upon found either free of infiltrates or affected by peri-insulitis (when the
infiltrates were limited to the connective tissues around the islets)the adoptive transfer of diabetogenic T cells but not
or by insulitis (when the islet itself was infiltrated). Pancreata induring the course of spontaneous diabetes. Unfortu-
which less than 20% of islets were infiltrated were defined as exhib-nately, this latter issue has been difficult to address
iting light insulitis. When less or more than 50% of islets was infil-because of the difficulty in detecting  cell death in
trated, pancreata were defined as exhibiting moderate and severe
spontaneously diabetic NOD mice due to the slow kinet- insulitis, respectively.
ics of the inflammatory process and the rapid clearance
of dead cells (Kurrer et al., 1997; O’Brien et al., 1997). Preparation of Pancreatic Islets
The bile duct was cannulated and the pancreas was distended withAlternatively, the level of CrmA expression required to
3 ml of DMEM containing 1 mg/ml of collagenase type V (Sigma).protect pancreatic  cells from apoptosis may be higher
The pancreas was then removed, incubated for 15 min at 37	C, andin spontaneous diabetes than in the adoptive transfer
disrupted by shaking. Islets were isolated after centrifugation overexperiments. In agreement with this latter hypothesis,
a Ficoll gradient prepared with 1.5 ml of 40% Ficoll in PBS overlaid
another strain of RIP-CrmA transgenic mice, in which with 1.5 ml of 23%, 1.5 ml of 20%, and 1.5 ml of 11%. Islets were
transgene expression was induced at high levels by picked individually under an inverted microscope.
tetracycline, has been shown to be partially protected
from both spontaneous and adoptively transferred dia- Purification of APCs
LN were cut in pieces and incubated for 40 min at 37	C in HBSSbetes (I. Millet, personal communication). Finally, the
containing 400 U/ml collagenase D (Roche) and 100 g/ml DNasetransgenic expression of CrmA in pancreatic  cells may
I (Sigma). Cells were resuspended in HBSS without Ca2 and Mg2inhibit the wave of  cell apoptosis, which occurs spon-
containing 5% FCS and 5 mM EDTA. CD11c cells and CD11c
taneously at 2 weeks of age in rodents (Trudeau et al., cells were purified using MACS CD11c (N418) MicroBeads (Miltenyi
2000). This wave of  cell death may actually result in Biotec, Paris, France). When indicated, purified CD11c cells were
the tolerization of potentially autoreactive T cells, and stained with anti-CD11b mAb, and CD11b and CD11b DCs were
purified by flow cytometry using a FACSvantage (Becton Dickinson).preventing this phenomenon in RIP-CrmA NOD mice
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Flow Cytometry tional to N.G. (1-1999-751) and A.L.(1-1998-113) and by grants from
the Etablissement Franc¸ais des Greffes, the Fondation Aupetit, andFor inducing  cell apoptosis in vitro, islets were incubated overnight
at 37	C in DMEM containing 10% FCS, penicillin (100 U/ml), and the Association de la Recherche pour le Cancer to N.G.
streptomycin (100 g/ml). The day after, islets were hand-picked
individually and incubated for 60 hr with IL-1 (10 U/ml) and IFN- Received May 11, 2001; revised November 30, 2001.
(150 U/ml; R&D Systems) with or without sCD95L (150 ng/ml; Alexis
Corporation, San Diego, CA). Islets were incubated for 5 min in PBS References
containing 0.4 mg/ml of EDTA, washed, and dissociated for 30 min
at 37	C in PBS containing BSA (20 mg/ml) and dispase I (0.68 mg/ml) Adler, A.J., Marsh, D.W., Yochum, G.S., Guzzo, J.L., Nigam, A.,
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4	C as described (Thomas et al., 1999). Nuclei were analyzed on a
Albers, R., de Heer, C., Bol, M., Bleumink, R., Seinen, W., and Pieters,
FACScan flow cytometer (Becton Dickinson).
R. (1998). Selective immunomodulation by the autoimmunity-induc-
For monitoring SZ-induced  cell apoptosis, islets were prepared
ing xenobiotics SZ and HgCl2. Eur. J. Immunol. 28, 1233–1242.
from SZ- and buffer-treated mice and cultured overnight at 37	C in
Albert, M.L., Pearce, S.F., Francisco, L.M., Sauter, B., Roy, P., Sil-5% CO2 and in DMEM containing 2.5 mM glucose supplemented
verstein, R.L., and Bhardwaj, N. (1998a). Immature DCs phagocytosewith 10% FCS, 20 mM HEPES (pH 7.4), and nonessential amino
apoptotic cells via v5 integrin and CD36, and cross-present Agacids. Islets were then dissociated with dispase. For monitoring the
to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359–1368.frequency of cells exhibiting fragmented nuclei, cells were incubated
Albert, M.L., Sauter, B., and Bhardwaj, N. (1998b). DCs acquire Agin a hypotonic fluorochrome solution and analyzed as described
from apoptotic cells and induce class I-restricted CTLs. Nature 392,above. For measuring the frequency of Annexin V-positive  cells,
86–89.cells were stained with PE-conjugated Annexin V and 7-AAD and
analyzed on a FACScan flow cytometer after gating on autofluores- Austyn, J.M. (1999). Death, destruction, danger and DCs. Nat. Med.
cent  cells as described (Thomas et al., 1999). 5, 1232–1233.
For monitoring the level of activation of CD11b DCs, purified Bendelac, A., Carnaud, C., Boitard, C., and Bach, J.F. (1987). Synge-
CD11c cells were stained with anti-CD11b (M1/70), anti-CD11c neic transfer of autoimmune diabetes from diabetic NOD mice to
(N418), and either anti-CD80 (1G10), anti-CD86 (GL1), anti-CD40 healthy neonates. Requirement for both L3T4 and Lyt-2 T cells.
(3/23), or anti-I-Ag7,d (M5/114). Cells were analyzed on a FACScan J. Exp. Med. 166, 823–832.
flow cytometer after gating on CD11cCD11b cells.
Christianson, S.W., Shultz, L.D., and Leiter, E.H. (1993). AdoptiveTo characterize the phenotype of T cells, LN cells were stained
transfer of diabetes into immunodeficient NOD-scid/scid mice: rela-with anti-CD4 (RM4-5), anti-Thy1.2 (30H12), anti-CD44 (IM7), and
tive contribution of CD4 and CD8 T-cells from diabetic versusanti-CD62L (MEL-14) mAb. Cells were analyzed on a FACScan flow
prediabetic NOD.NON-Thy-1a donors. Diabetes 42, 44–55.cytometer after gating on CD4Thy1.2 T cells.
Delovitch, T.L., and Singh, B. (1997). The NOD mouse as a model
of autoimmune diabetes: immune dysregulation gets the NOD. Im-T Cell Assays
munity 7, 727–738.For measuring IFN- secretion, 2 106 splenocytes were incubated
Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., andin FCS-containing DMEM in flat-bottom 96-well plates with or with-
Bhardwaj, N. (2001). Ag-specific inhibition of effector T cell functionout islet cells (2  104 cells/well), GAD65 (30 g/ml), or ConA (2
in humans after injection of immature DCs. J. Exp. Med. 193,g/ml). Supernatants were harvested 48 hr later and IFN- contents
233–238.were measured by ELISA.
For measuring IL-2 secretion, 1  105 BW2.5-31 hybridoma were Fo¨rster, I., Hirose, R., Arbeit, J., Clausen, B., and Hanahan, D. (1995).
incubated for 24 hr in FCS-containing DMEM in U-bottom 96-well Limited capacity for tolerization of CD4 T cells specific for a pancre-
plates with various numbers of CD11c cells. Supernatants were atic  cell neo-Ag. Immunity 2, 573–585.
analyzed for IL-2 content by ELISA. Fo¨rster, I., and Lieberam, I. (1996). Peripheral tolerance of CD4
For measuring T cell proliferation, CD4 cells were purified from T cells following local activation in adolescent mice. Eur. J. Immunol.
the spleen and the LN of BDC2.5 TCR transgenic mice by negative 26, 3194–3202.
depletion of CD8, CD11b, and B220 cells using Dynabeads (Dy-
Gallucci, S., Lolkema, M., and Matzinger, P. (1999). Natural adju-nal, Compie`gne, France). CD62Lhigh cells were purified by positive
vants: endogenous activators of DCs. Nat. Med. 5, 1249–1255.selection using MACS CD62L MicroBeads (Miltenyi Biotec). Purified
Hanahan, D. (1985). Heritable formation of pancreatic -cell tumoursCD62Lhigh CD4 T cells were labeled using 5, 6-Carboxy-Succinimi-
in transgenic mice expressing recombinant insulin/simian virus 40dyl-Fluorescein-Ester (CFSE) as described (Lyons and Parish, 1994).
oncogenes. Nature 315, 115–122.3  105 CFSE-labeled CD4 T cells were incubated with various
numbers of CD11c cells for 96 hr. T cell proliferation was assessed Haskins, K., and McDuffie, M. (1990). Acceleration of diabetes in
by measuring the decrease in CFSE fluorescence due to cell division young NOD mice with a CD4 islet-specific T cell clone. Science
on a FACScan flow cytometer. 249, 1433–1436.
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M.,
Adoptive Transfer Experiments Ravetch, J.V., Steinman, R.M., and Nussenzweig, M.C. (2001). DCs
When indicated, red blood cell-depleted splenocytes were depleted induce peripheral T cell unresponsiveness under steady state condi-
of either CD4 or CD8 T cells using Dynabeads, and the indicated tions in vivo. J. Exp. Med. 194, 769–780.
numbers of cells were injected i.v. into irradiated NOD, NOD SCID, Heath, W.R., Kurts, C., Miller, J.F.A.P., and Carbone, F.R. (1998).
or NOD RAG-2 KO mice. In other experiments, Thy1.2 CD62Lhigh Cross-tolerance: a pathway for inducing tolerance to peripheral tis-
T cells were prepared from BDC2.5 TCR transgenic mice, and 5  sue Ag. J. Exp. Med. 187, 1549–1553.
106 cells were injected i.v. into 4-week-old Thy1.1 congenic NOD
Huang, F.P., Platt, N., Wykes, M., Major, J.R., Powell, T.J., Jenkins,mice.
C.D., and MacPherson, G.G. (2000). A discrete subpopulation of
DCs transports apoptotic intestinal epithelial cells to T cell areas of
Acknowledgments
mesenteric LN. J. Exp. Med. 191, 435–444.
Inaba, K., Turley, S., Yamaide, F., Iyoda, T., Mahnke, K., Inaba, M.,We thank Dr. Carnaud and Virginie Joulin for helpful discussions
Pack, M., Subklewe, M., Sauter, B., Sheff, D., et al. (1998). Efficientand Dr. Chatenoud for reagents. S.H. and W.F. were supported
presentation of phagocytosed cellular fragments on the MHC classby fellowships from Ligue Nationale Contre le Cancer and Human
II products of DCs. J. Exp. Med. 188, 2163–2173.Frontier Science Organization, respectively. This work was sup-
ported by grants from the Juvenile Diabetes Foundation Interna- Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., and Enk, A.H. (2000).
Crosstolerance in NOD Mice
181
Induction of IL-10-producing, nonproliferating CD4 T cells with Sakaguchi, S. (2000). Regulatory T cells: key controllers of immuno-
logic self-tolerance. Cell 101, 455–458.regulatory properties by repetitive stimulation with allogeneic imma-
ture human DCs. J. Exp. Med. 192, 1213–1222. Sauter, B., Albert, M.L., Francisco, L., Larsson, M., Somersan, S.,
and Bhardwaj, N. (2000). Consequences of cell death: exposure toJudkowski, V., Pinilla, C., Schroder, K., Tucker, L., Sarvetnick, N.,
necrotic tumor cells, but not primary tissue cells or apoptotic cells,and Wilson, D.B. (2001). Identification of MHC class II-restricted
induces the maturation of immunostimulatory DCs. J. Exp. Med.peptide ligands, including a glutamic acid decarboxylase 65 se-
191, 423–434.quence, that stimulate diabetogenic T cells from transgenic BDC2.5
NOD mice. J. Immunol. 166, 908–917. Soderstrom, I., Bergman, M.L., Colucci, F., Lejon, K., Bergqvist, I.,
and Holmberg, D. (1996). Establishment and characterization ofKatz, J.D., Wang, B., Haskins, K., Benoist, C., and Mathis, D. (1993).
RAG-2 deficient NOD mice. Scand. J. Immunol. 43, 525–530.Following a diabetogenic T cell from genesis through pathogenesis.
Cell 74, 1089–1100. Steinman, R.M., Turley, S., Mellman, I., and Inaba, K. (2000). The
induction of tolerance by DCs that have captured apoptotic cells.Kolb, H. (1993). IDDM: lessons from the low-dose SZ model in mice.
J. Exp. Med. 191, 411–416.Diabetes Rev. 1, 116.
Tewari, M., and Dixit, V.M. (1995). Fas- and tumor necrosis factor-Klinkhammer, C., Dohle, C., and Gleichmann, H. (1989). T cell-depen-
induced apoptosis is inhibited by the poxvirus CrmA gene product.dent class II MHC Ag expression in vivo induced by the diabetogen
J. Biol. Chem. 270, 3255–3260.SZ. Immunobiology 180, 1–11.
Thomas, H.E., Darwiche, R., Corbett, J.A., and Kay, T.W. (1999).Kurrer, M.O., Pakala, S.V., Hanson, H.L., and Katz, J.D. (1997). Beta
Evidence that  cell death in the NOD mouse is Fas independent.cell apoptosis in T cell-mediated autoimmune diabetes. Proc. Natl.
J. Immunol. 163, 1562–1569.Acad. Sci. USA 94, 213–218.
Trudeau, J.D., Dutz, J.P., Arany, E., Hill, D.J., Fieldus, W.E., andKurts, C., Heath, W.R., Carbone, F.R., Allison, J., Miller, J.F.A.P.,
Finegood, D.T. (2000). Neonatal cell apoptosis: a trigger for autoim-and Kosaka, H. (1996). Constitutive class I-restricted exogenous
mune diabetes? Diabetes 49, 1–7.presentation of self Ag in vivo. J. Exp. Med. 184, 923–930.
Urban, B.C., Willcox, N., and Roberts, D.J. (2001). A role for CD36Kurts, C., Kosaka, H., Carbone, F.R., Miller, J.F.A.P., and Heath,
in the regulation of DC function. Proc. Natl. Acad. Sci. USA 98,W.R. (1997). Class I-restricted cross-presentation of exogenous self-
8750–8755.Ag leads to deletion of autoreactive CD8 T cells. J. Exp. Med. 186,
Van de Winkel, M., Maes, E., and Pipeleers, D. (1982). Islet cell239–245.
analysis and purification by light scatter and autofluorescence. Bio-Kurts, C., Miller, J.F.A.P., Subramaniam, R.M., Carbone, F.R., and
chem. Biophys. Res. Commun. 107, 525–532.Heath, W.R. (1998). MHC class I-restricted cross-presentation is
von Herrath, M.G., Dockter, J., and Oldstone, M.B. (1994). How virusbiased towards high dose Ag and those released during cellular
induces a rapid or slow onset IDDM in a transgenic model. Immunitydestruction. J. Exp. Med. 188, 409–414.
1, 231–242.
Kurts, C., Sutherland, R.M., Davey, G., Li, M., Lew, A.M., Blanas,
E., Carbone, F.R., Miller, J.F., and Heath, W.R. (1999). CD8 T cell
ignorance or tolerance to islet Ag depends on Ag dose. Proc. Natl.
Acad. Sci. USA 96, 12703–12707.
Laloux, V., Beaudoin, L., Jeske, D., Carnaud, C., and Lehuen, A.
(2001). NK T cell-induced protection against diabetes in V14-J281
transgenic NOD mice is associated with a Th2 shift circumscribed
regionally to the islets and functionally to islet autoantigens. J. Im-
munol. 166, 3749–3756.
Larger, E., Becourt, C., Bach, J.F., and Boitard, C. (1995). Pancreatic
islet  cells drive T cell-immune responses in the NOD mouse model.
J. Exp. Med. 181, 1635–1642.
Leiter, E.H. (1982). Multiple low-dose SZ-induced hyperglycemia
and insulitis in C57BL mice: influence of inbred background, sex,
and thymus. Proc. Natl. Acad. Sci. USA 79, 630–634.
Lyons, A.B., and Parish, C.R. (1994). Determination of lymphocyte
division by flow cytometry. J. Immunol. Methods 171, 131–137.
Mellman, I., and Steinman, R.M. (2001). DCs: specialized and regu-
lated Ag processing machines. Cell 106, 255–258.
Miller, J., and Heath, W. (1993). Self-ignorance in the peripheral
T-cell pool. Immunol. Rev. 133, 132–150.
O’Brien, B.A., Harmon, B.V., Cameron, D.P., and Allan, D.J. (1996).
 cell apoptosis is resonsible for the development of IDDM in the
multiple low-dose SZ model. J. Pathol. 178, 176–181.
O’Brien, B.A., Harmon, B.V., Cameron, D.P., and Allan, D.J. (1997).
Apoptosis is the mode of  cell death responsible for the develop-
ment of IDDM in the NOD mouse. Diabetes 46, 750–757.
Prochazka, M., Gaskins, H.R., Shultz, L.D., and Leiter, E.H. (1992).
The NOD scid mouse: model for spontaneous thymomagenesis as-
sociated with immunodeficiency. Proc. Natl. Acad. Sci. USA 89,
3290–3294.
Roncarolo, M.G., Levings, M.K., and Traversari, C. (2001). Differenti-
ation of T regulatory cells by immature DCs. J. Exp. Med. 193,
F5–F10.
Rubartelli, A., Poggi, A., and Zocchi, M.R. (1997). The selective en-
gulfment of apoptotic bodies by DCs is mediated by the (v)3
integrin and requires intracellular and extracellular calcium. Eur. J.
Immunol. 27, 1893–1900.
